A5019065438- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Bladder and Urothelial Cancer Treatments
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Hormonal and reproductive studies
- Web and Library Services
- Global Cancer Incidence and Screening
- Library Science and Information Literacy
- Radiomics and Machine Learning in Medical Imaging
- Child and Adolescent Health
- Management of metastatic bone disease
- Cancer survivorship and care
- Clinical practice guidelines implementation
- Genital Health and Disease
- Health Systems, Economic Evaluations, Quality of Life
- Child Abuse and Trauma
- Library Science and Administration
- Advances in Oncology and Radiotherapy
- Colorectal Cancer Screening and Detection
- Bone health and treatments
- Ethics and Legal Issues in Pediatric Healthcare
- Urologic and reproductive health conditions
- Radiation Dose and Imaging
University College London
2016-2025
University College London Hospitals NHS Foundation Trust
2016-2025
Royal London Hospital
2016-2025
The Prostate Centre
2006-2024
Marymount University
2024
Torbay Hospital
2024
University College Hospital
2013-2023
London Health Sciences Centre
2023
Royal College of Surgeons of England
2022-2023
Welsh Government
2022
No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Oct 2002Photodynamic Therapy for Prostate Cancer Recurrence After Radiotherapy: A Phase I Study Timothy R. Nathan, Douglas E. Whitelaw, Stanley C. Chang, William Lees, Paul M. Ripley, Heather Payne, Linda Jones, Constance Parkinson, Mark Emberton, Alison Gillams, Anthony Mundy, and Stephen G. Bown NathanTimothy Nathan , WhitelawDouglas Whitelaw ChangStanley Chang LeesWilliam Lees RipleyPaul Ripley PayneHeather Payne JonesLinda...
Objectives To assess the complications of transrectal (TR) compared to transperineal prostate (TP) biopsies. Patients and Methods Men diagnosed with cancer between 1 April 2014 31 March 2017 in England were identified National Prostate Cancer Audit. Administrative hospital data then used categorize type biopsy subsequent requiring admission. identify patients staying overnight immediately after those readmitted separately for admissions because sepsis, urinary retention or haematuria....
There are no universally monitored outcomes relevant to men with advanced prostate cancer, making it challenging compare health between populations. We sought develop a standard set of cancer follow during routine clinical care. The International Consortium for Health Outcomes Measurement assembled multidisciplinary working group the set. used modified Delphi method achieve consensus regarding outcomes, measures, and case mix factors included. 25 members international represented academic...
Objective To determine the impact of COVID‐19 pandemic on diagnostic and treatment activity in 2020 across hospital providers prostate cancer (PCa) care English National Health Service. Methods Diagnostic between 23 March (start first national lockdown England) 31 December was compared with same calendar period 2019. Patients newly diagnosed PCa were identified from rapid registration data linked to other electronic healthcare datasets. Results There a 30.8% reduction (22 419 vs 32 409)...
<h3>Abstract</h3> <b>Objective</b> To establish which attributes of conservative treatments for prostate cancer are most important to men. <b>Design</b> Discrete choice experiment. <b>Setting</b> Two London hospitals. <b>Participants</b> 129 men with non-metastatic cancer, mean age 70 years; 69 118 (58%) T stage 1 or 2 at diagnosis. <b>Main outcome measures</b> Men9s preferences for, and trade-offs between, the diarrhoea, hot flushes, ability maintain an erection, breast swelling tenderness,...
To report the final analysis of a Phase II trial, which investigated safety and efficacy specific endothelin A receptor antagonist zibotentan (AstraZeneca, Macclesfield, UK) in patients with metastatic castration-resistant prostate cancer (CRPC).Patients CRPC bone metastases who were pain free or mildly symptomatic for randomized to receive once-daily oral tablets 10 mg, 15 mg placebo. The primary endpoint was time progression secondary endpoints included overall survival, change number...
The objective of this study was to assess the impact <sup>68</sup>Ga-prostate-specific membrane antigen (<sup>68</sup>Ga-PSMA) PET/CT on management prostate cancer in patients with biochemical recurrence (BCR). <b>Methods:</b> Documented plans before and after <sup>68</sup>Ga-PSMA 100 BCR were retrospectively reviewed, changes recorded. <b>Results:</b> Management changed 39 (39%). occurred 23 (33.8%) 68 radical prostatectomy 16 (50%) 32 previously treated radiotherapy. Positive scan results...
PurposeEarly and accurate localization of lesions in patients with biochemical recurrence (BCR) prostate cancer may guide salvage therapy decisions. The present study, 18F-Fluciclovine PET/CT biochemicAL reCurrence Of Prostate caNcer (FALCON; NCT02578940), aimed to evaluate the effect 18F-fluciclovine on management men BCR cancer.Methods MaterialsMen a first episode after curative-intent primary were enrolled at 6 UK sites. Patients underwent positron emission tomography/computed tomography...
Aim To develop a management strategy (rehabilitation programme) for erectile dysfunction (ED) after radiotherapy (RT) or androgen deprivation therapy (ADT) prostate cancer that is suitable use in UK NHS healthcare context. Methods PubMed literature searches of ED this patient group together with survey 28 experts the treatment-induced from across were conducted. Results Data 19 articles and completed questionnaires collated. The findings discussed article confirm RT/ADT can significantly...
Robot-assisted radical prostatectomy (RARP) has been rapidly adopted without robust evidence comparing its functional outcomes against laparoscopic (LRP) or open retropubic (ORP) approaches. This study compared patient-reported following RARP, LRP ORP. All men diagnosed with prostate cancer in England during April – October 2014 who underwent were identified from the National Prostate Cancer Audit and mailed a questionnaire 18 months after diagnosis. Group differences sexual, urinary, bowel...
BackgroundEarly diagnosis of malignant spinal cord compression (SCC) is crucial because pretreatment neurological status the major determinant outcome. In metastatic castration-resistant prostate cancer, SCC a clinically significant cause disease-related morbidity and mortality. We investigated whether screening for with MRI, pre-emptive treatment if radiological (rSCC) was detected, reduced incidence clinical (cSCC) in asymptomatic patients cancer metastasis.MethodsWe did parallel-group,...
The use and duration of androgen deprivation therapy (ADT) with postoperative radiotherapy (RT) have been uncertain. RADICALS-HD compared adding no ("None"), 6-months ("Short"), or 24-mo ("Long") ADT to study efficacy in the long term.
The aim of this study was to examine the prevalence androgen receptor (AR) amplification in metastases bone and other sites patients with hormone-refractory prostate cancer (HRPC) compare these findings those pretreatment primary tumour samples from same patients. Tissue 24 HRPC available for study, together 13 specimens. AR gene copy number X-chromosome were assessed by fluorescence situ hybridization (FISH) using a SpectrumOrange-labelled probe at locus Xq11-13 SpectrumGreen-labelled...